Likewise, Clinica Universidad de Navarra conducted a Phase 1b, randomized, multicenter, open-label study (TARGET-I, NCT02197169) from 2014 to 2018, investigating conditional replicative adenovirus (DNX-2401) and interferon gamma (IFN-γ) for recurrent glioblastoma. This evidence concerns the gene IFNG and glioblastoma.